Allergan PLC. (NYSE:AGN)‘s stock had its “equal weight” rating reissued by investment analysts at Barclays PLC in a report issued on Monday.

AGN has been the topic of several other research reports. Cowen and Company set a $400.00 price target on shares of Allergan PLC. and gave the stock a “buy” rating in a research note on Thursday, June 8th. Mizuho cut their price objective on shares of Allergan PLC. from $275.00 to $267.00 and set a “buy” rating for the company in a research report on Friday, June 9th. Royal Bank Of Canada set a $284.00 price objective on shares of Allergan PLC. and gave the company a “buy” rating in a research report on Monday, June 12th. Cantor Fitzgerald initiated coverage on Allergan PLC. in a research note on Friday, June 16th. They issued a “neutral” rating and a $231.00 price objective for the company. Finally, BidaskClub upgraded Allergan PLC. from a “sell” rating to a “hold” rating in a research note on Saturday, June 17th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $271.84.

Allergan PLC. (AGN) opened at 209.80 on Monday. Allergan PLC. has a 12 month low of $184.50 and a 12 month high of $256.80. The stock has a 50 day moving average price of $220.20 and a 200 day moving average price of $233.72. The stock has a market capitalization of $70.14 billion, a PE ratio of 6.39 and a beta of 1.15.

Allergan PLC. (NYSE:AGN) last announced its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The company had revenue of $4.01 billion during the quarter, compared to analyst estimates of $3.95 billion. During the same period in the previous year, the business posted $3.35 earnings per share. The firm’s quarterly revenue was up 8.8% compared to the same quarter last year. On average, equities research analysts forecast that Allergan PLC. will post $16.22 earnings per share for the current fiscal year.

Allergan PLC. announced that its board has approved a share repurchase program on Monday, September 25th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the company to repurchase up to 2.8% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s management believes its shares are undervalued.

WARNING: “Allergan PLC. (AGN) Stock Rating Reaffirmed by Barclays PLC” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/10/04/allergan-plc-agn-stock-rating-reaffirmed-by-barclays-plc.html.

A number of institutional investors have recently made changes to their positions in AGN. Honeywell International Inc. increased its stake in Allergan PLC. by 13.6% in the 2nd quarter. Honeywell International Inc. now owns 168,130 shares of the company’s stock worth $40,871,000 after acquiring an additional 20,100 shares during the last quarter. Israel Discount Bank of New York bought a new position in shares of Allergan PLC. during the 1st quarter valued at approximately $988,000. Palladium Partners LLC boosted its position in shares of Allergan PLC. by 1.7% during the 2nd quarter. Palladium Partners LLC now owns 31,161 shares of the company’s stock valued at $7,575,000 after acquiring an additional 523 shares during the last quarter. DekaBank Deutsche Girozentrale bought a new position in shares of Allergan PLC. during the 2nd quarter valued at approximately $41,345,000. Finally, Aviva PLC boosted its position in shares of Allergan PLC. by 2.4% during the 2nd quarter. Aviva PLC now owns 287,455 shares of the company’s stock valued at $69,892,000 after acquiring an additional 6,722 shares during the last quarter. 82.03% of the stock is owned by institutional investors.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Analyst Recommendations for Allergan PLC. (NYSE:AGN)

Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.